Dolutegravir (DTG), sold under the brand name Tivicay, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. [6] . It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. [7] …

2019年7月24日 · Two drugs under consideration for inclusion in new regimens are dolutegravir (DTG), to replace EFV, and tenofovir alafenamide fumarate (TAF), to replace TDF, both prodrugs of tenofovir. 7,8 DTG has...

Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. [1] . It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil. [1] .

with newer antiretroviral (ARV) drugs – including body weight gain and other cardiometabolic risks, tolerability of regimens, safety in pregnancy and HIV drug resistance. The meeting participants reviewed data sources, including clinical trials, observational studies and programmatic data in the context of digitalization, that can inform future

Dolutegravir/rilpivirine (DTG/RPV) was approved by the US Food and Drug Administration (FDA) as the first dual antiretroviral STR for the maintenance therapy of HIV-1 infection.

2025年1月1日 · TLD is a generic HIV combination. It contains tenofovir disoproxil, lamivudine and dolutegravir. Sometime the tablet are marked LTD. TLD is a very good combination and is now the most widely used ART. It is recommended by the WHO. This combination is only available in either low or middle-income countries.

2023年12月21日 · Dolutegravir (DTG) has been recommended by the WHO for use in second-line antiretroviral therapy (ART) regimens since 2019. 1 The recommendation followed the findings of the multicountry, multicentre DAWNING trial, which showed superior viral suppression and fewer adverse events with DTG compared with a boosted lopinavir (LPV)-based regimen in p...

TLD is a fixed-dose combination of TDF 300 mg, 3TC 300 mg, and DTG 50 mg. TLD is also recommended for use as a second-line regimen for patients failing on efavirenz- or nevirapine-containing regimens or for those failing a non-DTG-containing first-line regimen. WHY TRANSITION FROM TLE TO TLD?

Dolutegravir (DTG) in combination with abacavir/lamivudine (ABC/3TC) is one of these preferred regimens in multiple clinical scenarios, including treatment-naive and treatment-experienced patients.

Dolutegravir is a medication used to treat HIV, marketed under the brand name Tivicay. It is taken in combination with other antiretroviral drugs. The usual adult dose of dolutegravir is one 50mg tablet once a day. If you are taking certain other medications, you may be prescribed a dose of one 50mg tablet twice a day.